Philadelphia Pharmaceuticals Co. (PHIL) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hayat Pharmaceutical Industries Co. Ltd.

Philadelphia Pharmaceuticals Co.

Dar Al Dawa Development & Investment Co. Ltd.

Why is Philadelphia Pharmaceuticals Co. ?

Flat results in Jun 25

DEBTORS TURNOVER RATIO(HY) Lowest at 1.26%

With ROE of 7.02%, it has a attractive valuation with a 0.00 Price to Book Value

Over the past year, while the stock has generated a return of 3.33%, its profits have risen by 9%

Underperformed the market in the last 1 year

The stock has generated a return of 3.33% in the last 1 year, much lower than market (Jordan General Index) returns of 41.30%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Philadelphia Pharmaceuticals Co. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Philadelphia Pharmaceuticals Co.

3.33%

0.35

19.54%

Jordan General Index

41.13%

4.48

9.22%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.97%

EBIT Growth (5y)

4.45%

EBIT to Interest (avg)

1.03

Debt to EBITDA (avg)

0.32

Net Debt to Equity (avg)

0.05

Sales to Capital Employed (avg)

0.58

Tax Ratio

21.07%

Dividend Payout Ratio

63.93%

Pledged Shares

Institutional Holding

ROCE (avg)

7.95%

ROE (avg)

4.90%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

0.63

EV to EBITDA

0.50

EV to Capital Employed

0.07

EV to Sales

0.10

PEG Ratio

Dividend Yield

ROCE (Latest)

10.62%

ROE (Latest)

7.02%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

OPERATING CASH FLOW(Y)

Highest at JOD 1.22 MM

ROCE(HY)

Highest at 7.13%

NET SALES(Q)

Highest at JOD 2.44 MM

RAW MATERIAL COST(Y)

Fallen by 0.24% (YoY

CASH AND EQV(HY)

Highest at JOD 3.4 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.86%

OPERATING PROFIT(Q)

Highest at JOD 0.56 MM

OPERATING PROFIT MARGIN(Q)

Highest at 22.78 %

PRE-TAX PROFIT(Q)

Highest at JOD 0.36 MM

NET PROFIT(Q)

Highest at JOD 0.28 MM

EPS(Q)

Highest at JOD 0.04

-1What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.26%

Here's what is working for Philadelphia Pharmaceuticals Co.

Net Sales

Highest at JOD 2.44 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (JOD MM)

Operating Cash Flow

Highest at JOD 1.22 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (JOD MM)

Operating Profit

Highest at JOD 0.56 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JOD MM)

Operating Profit Margin

Highest at 22.78 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at JOD 0.36 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JOD MM)

Net Profit

Highest at JOD 0.28 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JOD MM)

EPS

Highest at JOD 0.04

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (JOD)

Cash and Eqv

Highest at JOD 3.4 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 2.86%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by 0.24% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Philadelphia Pharmaceuticals Co.

Debtors Turnover Ratio

Lowest at 1.26%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio